Using whole genome sequencing, Orchid helps families screen for diseases that could affect their chance of having a successful pregnancy and healthy baby.

Orchid's cutting-edge whole genome embryo screening is performed as part of the IVF process. The embryo screening combines Preimplantation Genetic Testing for Aneuploidy (PGT-A), Preimplantation Genetic Testing for Monogenic/Single Gene Defects (PGT-M), and screens for hundreds of genes linked to severe monogenic diseases.

Orchid obtains 100x more data, and reads >99%* of an embryo's genome (compared to <1% that our competitors read). This is all done using the same 5-6 cell trophectoderm biopsy that other preimplantation genetic tests use. With this advanced data, Orchid can detect conditions that other tests miss.

* Percentage is based on validation studies using genomic regions of National Institute of Standards and Technology - GIAB samples

Orchid offers several advantages over existing PGT methodologies. These include faster turnaround times, the ability to detect conditions that other tests may miss, and a comprehensive single screen that includes PGT-A, PGT-M, and gene panels. Moreover, Orchid provides one-on-one genetic counseling for all patients at no additional charge.

The technology behind Orchid has been developed by experts in medical genetics, embryology, and assisted reproductive technology.

Jacques Cohen, PhD

Pioneering Embryologist and foundational figure in IVF and ART innovation

Roohi Jeelani, MD

Double board certified Reproductive Endocrinologist and Infertility Specialist (REI)

Lusine Aghajanova, MD, PhD

Clinical Assistant Professor at the Stanford Medical Center

Barry Behr, PhD

Professor of Obstetrics and Gynecology Emeritus at the Stanford Medical Center

Jan Liphardt, PhD

Professor of Bioengineering at Stanford University

Nathan Slotnick, MD, PhD

Perinatologist and Medical Geneticist

Amber Cooper, MD

Double board certified Obstetrics and Gynecologist and Reproductive Endocrinologist and Infertility Specialist

As the world's first comprehensive whole genome embryo screening solution, Orchid represents a significant advancement in genetic testing for family planning. Our premium service reads >99% of an embryo's genome, providing unparalleled insight into your future child's health compared to traditional genetic testing methods that only look at <1%.

While our cutting-edge technology and thorough analysis reflect our premium pricing, we understand that building a family is a significant investment. That's why we've partnered with CapexMD to make Orchid more accessible to growing families.

CapexMD specializes in patient financing services for all fertility treatment options. They offer a streamlined financing experience with:

• Easy & secure online application process
• Personal attention and concierge-level service to reduce stress
• Flexible payment terms with no membership fees
• No annual fees
• No prepayment penalties